Difference between revisions of "Part:BBa K3064010"
Line 20: Line 20:
 
<partinfo>BBa_K3064010 parameters</partinfo>
 
<partinfo>BBa_K3064010 parameters</partinfo>
 
<!-- -->
 
<!-- -->
 +
 +
===References===
 +
 +
 +
 +
1.TRIM21[G/OL]. https://en.wikipedia.org/wiki/TRIM21, 2019.
 +
 +
2.Stian Foss, Ruth Watkinson, Inger Sandlie, et al. TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity[J]. Immunological Reviews, 2015, 268(1):328-339.
 +
 +
3.Lee AYS. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity[J]. Rheumatology International, 2017, 37(8):1323-1333.

Revision as of 02:57, 29 September 2019


mmuTrim21

It is a known type of E3 ubiquitin-protein ligase as an intracellular antibody effector in the antibody-mediated proteolysis pathway.

Usage and Biology

Trim 21 has a particular domain to recognize the Fc domain and combine with antibody marked no-enveloped virions. Using its E3 ubiquitin-protein ligase activity, trim 21 with the antibody bond to virons is degraded by the Ubiquitin dependent protease degradation pathway.

Due to the organism, therapeutic antibodies targeting disease-associated antigens in extracellular is a key tool for some certain diseases in current researches. Although some diseases is not caused by virons, trim 21 can be used in these diseased by blocking a particular pathogenic process.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BamHI site found at 75
    Illegal BamHI site found at 778
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 176
  • 1000
    COMPATIBLE WITH RFC[1000]


References

1.TRIM21[G/OL]. https://en.wikipedia.org/wiki/TRIM21, 2019.

2.Stian Foss, Ruth Watkinson, Inger Sandlie, et al. TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity[J]. Immunological Reviews, 2015, 268(1):328-339.

3.Lee AYS. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity[J]. Rheumatology International, 2017, 37(8):1323-1333.